[144] Cellebrite DI Ltd. Warrants SEC Filing

Rhea-AI Filing Summary

Cellebrite DI Ltd. (CLBTW) reported a proposed sale of 2,799 common shares through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $44,532.09, and notes the securities were acquired as Restricted Stock Units on 08/20/2025. The filing shows recent dispositions by the same person: a sale of 2,874 shares on 08/21/2025 for $44,489.52 and a 10b5-1 plan sale of 12,150 shares on 05/23/2025 for $207,980.06. The filer certifies no undisclosed material adverse information and, where applicable, indicates reliance on a written 10b5-1 plan or trading instructions. This notice documents the planned transaction, the acquisition as RSUs, broker details, shares outstanding (244,469,106) and provides transparency about recent insider sales.

Positive

• Acquisition method disclosed: Securities were acquired as Restricted Stock Units, clarifying origin of the shares
• Broker and exchange details provided: Sale to occur via Morgan Stanley Smith Barney on NASDAQ, aiding transparency
• Prior 10b5-1 sale disclosed: May 23, 2025 sale under a 10b5-1 plan demonstrates use of a preauthorized trading plan

Negative

• Insider selling activity: The filer reported recent sales of 2,874 and 12,150 shares in the past three months, increasing share supply from insiders
• No operational or financial context provided: The filing contains only transaction disclosure and does not disclose company performance or rationale for the sales

Insights

Securities Analyst

TL;DR: Routine insider disclosure showing modest planned sale and prior 10b5-1 program sales; no new operational data disclosed.

The Form 144 provides required transparency on an executive or insider sale: 2,799 shares to be sold via Morgan Stanley with explicit reporting of acquisition as Restricted Stock Units and recent sales of 2,874 and 12,150 shares. The filing does not include financial results or operational updates, so its investor impact is limited to share supply and insider liquidity signaling. The presence of a 10b5-1 plan for the May sale suggests pre‑planned disposition rather than opportunistic trading. Monitor aggregate insider activity for trend analysis, but this single notice is informational rather than material to company fundamentals.

Compliance / Corporate Governance Expert

TL;DR: Filing appears procedurally complete for a Rule 144 notice and discloses prior 10b5-1 sales; no compliance red flags visible in the text provided.

The form documents the nature of acquisition (RSUs), broker details, and seller representations, including a certification about undisclosed material adverse information. It also records recent sales under a 10b5-1 arrangement, which supports compliance with insider-trading rules. The notice lacks any contradictory statements or omitted procedural elements within the provided text. As always, investors and compliance officers should reconcile dates and volumes against company insider transaction records, but based solely on this content the disclosure meets Rule 144 reporting expectations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2799	44532.09	244469106	08/22/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/20/2025	Restricted Stock Units	Issuer			2799	08/20/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
DAVID GEE 94 Shlomo Shmelzer Road Petah Tikva L3 4970602	Common	08/21/2025	2874	44489.52
10b5-1 Sales for DAVID N GEE 94 Shlomo Shmelzer Road Petah Tikva L3 4970602	COMMON	05/23/2025	12150	207980.06

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the CLBTW Form 144 disclose about the proposed sale?

The notice discloses a proposed sale of 2,799 common shares via Morgan Stanley Smith Barney on NASDAQ, with aggregate market value of $44,532.09.

How were the securities being sold acquired according to the filing?

The securities were acquired as Restricted Stock Units (RSUs) on 08/20/2025, with 2,799 units reported.

Did the filer report any recent sales in the past three months?

Yes; the filing lists sales of 2,874 shares on 08/21/2025 for $44,489.52 and a 10b5-1 sale of 12,150 shares on 05/23/2025 for $207,980.06.

Does the filing state whether the seller knows of undisclosed material information?

The filer represents by signing that they do not know any material adverse information about the issuer that has not been publicly disclosed.

What is the total number of shares outstanding reported in the filing?

The form reports 244,469,106 shares outstanding.

Who is the broker handling the proposed sale?

The broker listed is Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.